NEW YORK, Oct. 10, 2024 (GLOBE NEWSWIRE) — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of JFrog Ltd. (“JFrog” or “the Company”) (NASDAQ: FROG). Investors who purchased JFrog securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/FROG.
Investigation Details
On August 7, 2024, JFrog released its second quarter 2024 financial results and lowered its fiscal year 2024 guidance, stating that it “expect[s] cloud revenue growth to slow relative to prior expectations.” On this news, JFrog’s stock price fell $9.37 per share, or 27.5%, to close at $34.05 per share on August 7, 2024.
What’s Next?
If you are aware of any facts relating to this investigation or purchased JFrog securities, you can assist this investigation by visiting the firm’s site: bgandg.com/FROG. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com
- Prairie Provident Resources Announces Successful Basal Quartz Drilling Program and First Quarter 2025 Results - May 13, 2025
- FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC Continues Lead Plaintiff Search for Viatris Inc. (VTRS) Securities Fraud Class Action - May 13, 2025
- Belite Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update - May 13, 2025
